vimarsana.com
Home
Live Updates
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights : vimarsana.com
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438--...
Related Keywords
United States ,
Boston ,
Massachusetts ,
Davidj Woodhouse ,
,
Merck Sharp Dohme ,
Merck Co Inc ,
Merck Sharp Dohme Corp ,
Anesiva Inc ,
Exchange Commission ,
Shasqi Inc ,
Coherus Biosciences Inc ,
Blade Therapeutics Inc ,
Dexus Inc ,
Caredx Inc ,
Biopharmaceuticals Inc ,
Xdx Inc ,
Tularik Inc ,
Chief Financial Officer ,
Liver Meeting ,
Chief Executive Officer ,
Third Quarter ,
Coherus Biosciences ,
Blade Therapeutics ,
Merck Sharp ,
Dohme Corp ,
Alphabetical Order ,
Immunoglobin Like Transcript ,
Leukocyte Associated Immunoglobulin Like Receptor ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
United States Securities ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.